221 related articles for article (PubMed ID: 28055970)
1. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.
Ma J; Setton J; Morris L; Albornoz PB; Barker C; Lok BH; Sherman E; Katabi N; Beal K; Ganly I; Powell SN; Lee N; Chan TA; Riaz N
Oncotarget; 2017 Feb; 8(6):10312-10323. PubMed ID: 28055970
[TBL] [Abstract][Full Text] [Related]
2. A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas.
Liu N; Boohaker RJ; Jiang C; Boohaker JR; Xu B
Oncotarget; 2015 Oct; 6(33):34649-57. PubMed ID: 26452218
[TBL] [Abstract][Full Text] [Related]
3. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.
Sun L; Wang RC; Zhang Q; Guo LL
Pathol Res Pract; 2020 Aug; 216(8):153032. PubMed ID: 32703496
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
5. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract][Full Text] [Related]
6. Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma.
Mansour WY; Bogdanova NV; Kasten-Pisula U; Rieckmann T; Köcher S; Borgmann K; Baumann M; Krause M; Petersen C; Hu H; Gatti RA; Dikomey E; Dörk T; Dahm-Daphi J
Radiother Oncol; 2013 Jan; 106(1):147-54. PubMed ID: 23199656
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Weber AM; Drobnitzky N; Devery AM; Bokobza SM; Adams RA; Maughan TS; Ryan AJ
Oncotarget; 2016 Sep; 7(38):60807-60822. PubMed ID: 27602502
[TBL] [Abstract][Full Text] [Related]
9. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract][Full Text] [Related]
10. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.
Pitter KL; Casey DL; Lu YC; Hannum M; Zhang Z; Song X; Pecorari I; McMillan B; Ma J; Samstein RM; Pei IX; Khan AJ; Braunstein LZ; Morris LGT; Barker CA; Rimner A; Alektiar KM; Romesser PB; Crane CH; Yahalom J; Zelefsky MJ; Scher HI; Bernstein JL; Mandelker DL; Weigelt B; Reis-Filho JS; Lee NY; Powell SN; Chan TA; Riaz N; Setton J
J Natl Cancer Inst; 2021 Mar; 113(3):266-273. PubMed ID: 32726432
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
Chung CH; Guthrie VB; Masica DL; Tokheim C; Kang H; Richmon J; Agrawal N; Fakhry C; Quon H; Subramaniam RM; Zuo Z; Seiwert T; Chalmers ZR; Frampton GM; Ali SM; Yelensky R; Stephens PJ; Miller VA; Karchin R; Bishop JA
Ann Oncol; 2015 Jun; 26(6):1216-1223. PubMed ID: 25712460
[TBL] [Abstract][Full Text] [Related]
13. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
14. ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients.
Agostini LP; Stur E; Garcia FM; Ventorim DP; Dos Reis RS; Dettogni RS; Dos Santos EVW; Peterle GT; Maia LL; Mendes SO; de Carvalho MB; Tajara EH; de Paula F; Dos Santos M; da Silva AMA; Louro ID
Genet Test Mol Biomarkers; 2017 Dec; 21(12):727-735. PubMed ID: 29135311
[TBL] [Abstract][Full Text] [Related]
15. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
16. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
[TBL] [Abstract][Full Text] [Related]
17. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
Li Q; Hou J; Hu Z; Gu B; Shi Y
Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
[TBL] [Abstract][Full Text] [Related]
18. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects.
Iannuzzi CM; Atencio DP; Green S; Stock RG; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):606-13. PubMed ID: 11849780
[TBL] [Abstract][Full Text] [Related]
19. High pATM is Associated With Poor Local Control in Supraglottic Cancer Treated With Radiotherapy.
Bruine de Bruin L; Schuuring E; de Bock GH; Slagter-Menkema L; Mastik MF; Noordhuis MG; Langendijk JA; Kluin PM; van der Laan BFAM
Laryngoscope; 2020 Aug; 130(8):1954-1960. PubMed ID: 32275333
[TBL] [Abstract][Full Text] [Related]
20. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
